Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma

Published:2009-04-28 Issue:S10 Volume:115 Page:2346-2354
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Zurita Amado J.¹,Jonasch Eric¹,Wu Hua‐Kang²,Tran Hai T.²,Heymach John V.²³

Affiliation:

1. Department of Genitourinary Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

2. Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

3. Department of Thoracic/Head and Neck Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Funder

Genentech; Novartis Pharmaceuticals, Pfizer, Inc., and Wyeth Pharmaceuticals

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.24228

Reference66 articles.

1. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

2. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

3. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

4. Targeting HIF-1 for cancer therapy

5. VASCULAR ENDOTHELIAL GROWTH FACTOR AS PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers;Drug Resistance Updates;2023-03

2. Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma;Journal for ImmunoTherapy of Cancer;2019-12

3. Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213);Pediatric Blood & Cancer;2018-01-02

4. A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients;CPT: Pharmacometrics & Systems Pharmacology;2017-05-26

5. Anti-angiogenesis target therapy for advanced osteosarcoma;Oncology Reports;2017-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3